Preparation of gelatin nanoparticles with EGFR selection ability via biotinylated-EGF conjugation for lung cancer targeting

Ching Li Tseng, Feng Huei Lin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Lung cancer is the most malignant cancer today, and specific drug delivery has been developed for superior outcome. In this study, gelatin nanoparticles (GPs) were firstly employed as native carriers. Second, NeutrAvidin FITC was then grafted on the particle surface (GP-Av); finally much more amount of biotinylated EGF were able to be conjugated with NeutrAvidin FITC forming ligand- binding nanoparticles (GP-Av-bEGF) to enhance the targeting efficiency. These nanoparticles were applied as EGFR-seeking agents to detect lung cancer cells. Results of particle characterization show that the modification process had no influence on size (230 nm). Round and smooth nanoparticles were observed by AFM. The surface property of nanoparticles was characterized by surface plasmon resonance (SPR) and flowcytometry analysis as well as by examining the interaction of the modified EGF on particle surface with the ability to recognize EGFR. The binding ability of GPs with or without EGF modification is different. SPR assay showed that EGF-conjugated particles (GP-Av-bEGF) have stronger and faster bonding signal than the unmodified one (GP-Av). Free EGF competition results from SPR and A549 cell (lung adenocarcinoma cells) culture also confirmed the EGF receptormediated endocytosis mechanism for nanoparticles with EGF-modified binding. The in vitro targeting ability was confirmed by the uptake rate of different cells via flow cytometry assay. GP-Av-bEGF resulted in higher entrance efficiency on A549 than on normal lung cells (HFL1) and U2-OS (osteosarcoma cells) due to A549 possessing more amounts of EGFR. The targeting ability of GP-Av-bEGF nanoparticles with specific EGFR tracing ability was proved, which holds promise for further anticancer drug applications.

Original languageEnglish
Pages (from-to)161-169
Number of pages9
JournalBiomedical Engineering - Applications, Basis and Communications
Volume20
Issue number3
Publication statusPublished - Jun 2008
Externally publishedYes

Fingerprint

Gelatin
Epidermal Growth Factor
Nanoparticles
Lung Neoplasms
Surface Plasmon Resonance
Surface plasmon resonance
Fluorescein-5-isothiocyanate
Assays
Flow cytometry
Surface Properties
Osteosarcoma
Endocytosis
Drug delivery
Cell culture
Pharmaceutical Preparations
Surface properties
Flow Cytometry
Cell Culture Techniques
Ligands
Cells

Keywords

  • Avidin-biotin
  • Cancer
  • EGF
  • Gelatin
  • Nanoparticles

ASJC Scopus subject areas

  • Biophysics
  • Biomedical Engineering
  • Bioengineering

Cite this

@article{dc89b9b277a945229c3fe198b430d3f0,
title = "Preparation of gelatin nanoparticles with EGFR selection ability via biotinylated-EGF conjugation for lung cancer targeting",
abstract = "Lung cancer is the most malignant cancer today, and specific drug delivery has been developed for superior outcome. In this study, gelatin nanoparticles (GPs) were firstly employed as native carriers. Second, NeutrAvidin FITC was then grafted on the particle surface (GP-Av); finally much more amount of biotinylated EGF were able to be conjugated with NeutrAvidin FITC forming ligand- binding nanoparticles (GP-Av-bEGF) to enhance the targeting efficiency. These nanoparticles were applied as EGFR-seeking agents to detect lung cancer cells. Results of particle characterization show that the modification process had no influence on size (230 nm). Round and smooth nanoparticles were observed by AFM. The surface property of nanoparticles was characterized by surface plasmon resonance (SPR) and flowcytometry analysis as well as by examining the interaction of the modified EGF on particle surface with the ability to recognize EGFR. The binding ability of GPs with or without EGF modification is different. SPR assay showed that EGF-conjugated particles (GP-Av-bEGF) have stronger and faster bonding signal than the unmodified one (GP-Av). Free EGF competition results from SPR and A549 cell (lung adenocarcinoma cells) culture also confirmed the EGF receptormediated endocytosis mechanism for nanoparticles with EGF-modified binding. The in vitro targeting ability was confirmed by the uptake rate of different cells via flow cytometry assay. GP-Av-bEGF resulted in higher entrance efficiency on A549 than on normal lung cells (HFL1) and U2-OS (osteosarcoma cells) due to A549 possessing more amounts of EGFR. The targeting ability of GP-Av-bEGF nanoparticles with specific EGFR tracing ability was proved, which holds promise for further anticancer drug applications.",
keywords = "Avidin-biotin, Cancer, EGF, Gelatin, Nanoparticles",
author = "Tseng, {Ching Li} and Lin, {Feng Huei}",
year = "2008",
month = "6",
language = "English",
volume = "20",
pages = "161--169",
journal = "Journal of Chinese Corrosion Engineering",
issn = "1016-2372",
publisher = "World Scientific Publishing Co. Pte Ltd",
number = "3",

}

TY - JOUR

T1 - Preparation of gelatin nanoparticles with EGFR selection ability via biotinylated-EGF conjugation for lung cancer targeting

AU - Tseng, Ching Li

AU - Lin, Feng Huei

PY - 2008/6

Y1 - 2008/6

N2 - Lung cancer is the most malignant cancer today, and specific drug delivery has been developed for superior outcome. In this study, gelatin nanoparticles (GPs) were firstly employed as native carriers. Second, NeutrAvidin FITC was then grafted on the particle surface (GP-Av); finally much more amount of biotinylated EGF were able to be conjugated with NeutrAvidin FITC forming ligand- binding nanoparticles (GP-Av-bEGF) to enhance the targeting efficiency. These nanoparticles were applied as EGFR-seeking agents to detect lung cancer cells. Results of particle characterization show that the modification process had no influence on size (230 nm). Round and smooth nanoparticles were observed by AFM. The surface property of nanoparticles was characterized by surface plasmon resonance (SPR) and flowcytometry analysis as well as by examining the interaction of the modified EGF on particle surface with the ability to recognize EGFR. The binding ability of GPs with or without EGF modification is different. SPR assay showed that EGF-conjugated particles (GP-Av-bEGF) have stronger and faster bonding signal than the unmodified one (GP-Av). Free EGF competition results from SPR and A549 cell (lung adenocarcinoma cells) culture also confirmed the EGF receptormediated endocytosis mechanism for nanoparticles with EGF-modified binding. The in vitro targeting ability was confirmed by the uptake rate of different cells via flow cytometry assay. GP-Av-bEGF resulted in higher entrance efficiency on A549 than on normal lung cells (HFL1) and U2-OS (osteosarcoma cells) due to A549 possessing more amounts of EGFR. The targeting ability of GP-Av-bEGF nanoparticles with specific EGFR tracing ability was proved, which holds promise for further anticancer drug applications.

AB - Lung cancer is the most malignant cancer today, and specific drug delivery has been developed for superior outcome. In this study, gelatin nanoparticles (GPs) were firstly employed as native carriers. Second, NeutrAvidin FITC was then grafted on the particle surface (GP-Av); finally much more amount of biotinylated EGF were able to be conjugated with NeutrAvidin FITC forming ligand- binding nanoparticles (GP-Av-bEGF) to enhance the targeting efficiency. These nanoparticles were applied as EGFR-seeking agents to detect lung cancer cells. Results of particle characterization show that the modification process had no influence on size (230 nm). Round and smooth nanoparticles were observed by AFM. The surface property of nanoparticles was characterized by surface plasmon resonance (SPR) and flowcytometry analysis as well as by examining the interaction of the modified EGF on particle surface with the ability to recognize EGFR. The binding ability of GPs with or without EGF modification is different. SPR assay showed that EGF-conjugated particles (GP-Av-bEGF) have stronger and faster bonding signal than the unmodified one (GP-Av). Free EGF competition results from SPR and A549 cell (lung adenocarcinoma cells) culture also confirmed the EGF receptormediated endocytosis mechanism for nanoparticles with EGF-modified binding. The in vitro targeting ability was confirmed by the uptake rate of different cells via flow cytometry assay. GP-Av-bEGF resulted in higher entrance efficiency on A549 than on normal lung cells (HFL1) and U2-OS (osteosarcoma cells) due to A549 possessing more amounts of EGFR. The targeting ability of GP-Av-bEGF nanoparticles with specific EGFR tracing ability was proved, which holds promise for further anticancer drug applications.

KW - Avidin-biotin

KW - Cancer

KW - EGF

KW - Gelatin

KW - Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=56549129583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56549129583&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:56549129583

VL - 20

SP - 161

EP - 169

JO - Journal of Chinese Corrosion Engineering

JF - Journal of Chinese Corrosion Engineering

SN - 1016-2372

IS - 3

ER -